Skip to main content

Advertisement

Table 3 Baseline levels of the measured markers according to different clinical conditions

From: vWF/ADAMTS13 is associated with on-aspirin residual platelet reactivity and clinical outcome in patients with stable coronary artery disease

   n vWF (%) ADAMTS13 antigen (ng/mL) ADAMTS13 activity (IU/mL) Ratio antigen Ratio activity
Age > median (62 years) + 500 110 (88, 137) 519 (455, 581) 1.00 (0.79, 1.15) 0.21 (0.17, 0.29) 117 (86, 170)
500 100 (79, 127) 547 (467, 627) 1.05 (0.90, 1.21) 0.19 (0.14, 0.25) 97 (70, 136)
p   < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
Sex (female) + 218 106 (82, 136) 549 (463, 622) 1.04 (0.84, 1.19) 0.20 (0.14, 0.26) 111 (76, 157)
782 106 (83, 133) 525 (460, 596) 1.02 (0.82, 1.19) 0.20 (0.15, 0.27) 106 (77, 150)
p   0.840 0.052 0.877 0.611 0.726
Diabetes + 200 111 (83, 141) 557 (465, 639) 1.05 (0.81, 1.18) 0.20 (0.15, 0.27) 117 (84, 170)
800 105 (83, 131) 524 (459, 596) 1.02 (0.83, 1.19) 0.20 (0.15, 0.26) 106 (76, 147)
p   0.023 0.003 0.931 0.602 0.059
Hypertension + 556 104 (80, 132) 530 (463, 606) 1.01 (0.79, 1.16) 0.20 (0.15, 0.26) 107 (76, 150)
443 108 (86, 134) 533 (458, 607) 1.05 (0.86, 1.21) 0.20 (0.16, 0.28) 106 (77, 153)
p   0.033 0.959 0.034 0.081 0.962
Previous CVD + 635 110 (86, 137) 534 (463, 608) 1.02 (0.82, 1.19) 0.20 (0.16, 0.27) 110 (82, 160)
364 98 (78, 126) 525 (456, 602) 1.04 (0.85, 1.18) 0.19 (0.14, 0.25) 103 (72, 136)
p   < 0.001 0.453 0.663 0.001 0.002
Smokers + 203 107 (88, 134) 520 (441, 590) 1.03 (0.86, 1.19) 0.20 (0.16, 0.28) 108 (78, 151)
796 105 (83, 133) 532 (466, 607) 1.02 (0.82, 1.18) 0.20 (0.15, 0.26) 107 (77, 152)
p   0.621 0.100 0.306 0.515 0.796
  1. Values are given as median (25th, 75th percentiles)
  2. p-values refer to differences in the measured marker between patients having the specified clinical condition or not
  3. Significant p-values are highlighted with boldface